Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could this pill ease symptoms of a tough dementia?

NCT ID NCT05225415

Symptom relief Sponsor: Cognition Therapeutics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called CT1812 in 130 people with mild to moderate Dementia with Lewy Bodies. Over 6 months, researchers checked if the drug was safe and if it helped with thinking, sleep, or other symptoms. The goal was to see if it might ease the burden of this challenging condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

130 people

The number who actually took part.

Started

May 2022

Finished

Nov 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men or women 50-85 years of age (inclusive), meeting criteria for probable Dementia with Lewy Bodies (DLB). * MRI, or CT scan due to contraindication of MRI if approved by medical monitor) obtained during screening consistent with the clinical diagnosis of DLB and without findings of significant exclusionary abnormalities. An historical MRI (or CT scan), up to 1 year prior to screening, may be used if there is no history of intervening neurologic disease or clinical events (such as a stroke, head trauma etc.) and the subject is without clinical symptoms or signs suggestive of such intervening events. * MMSE 18-27 inclusive Exclusion Criteria: * Any neurological condition that may be contributing to cognitive impairment above and beyond those caused by the subject's DLB, including any co-morbidities detected by clinical assessment or MRI (or CT scan due to contraindication of MRI, if approved by medical monitor) * Screening MRI (or historical MRI or CT scan due to contraindication of MRI if approved by medical monitor) or historical MRI/CT scan, if applicable. of the brain indicative of significant abnormality, including, but not limited to, prior hemorrhage or infarct \> 1 cm3, \>3 lacunar infarcts, cerebral contusion, encephalomalacia, aneurysm, vascular malformation, subdural hematoma, hydrocephalus, space-occupying lesion (e.g. abscess or brain tumor such as meningioma). If a small incidental meningioma is observed, the medical monitor may be contacted to discuss eligibility. * Clinical, laboratory findings or medical history consistent with: 1. Other primary degenerative dementia (fronto-temporal dementia, Huntington's disease, Creutzfeldt-Jakob Disease, Down syndrome, etc.). 2. Other neurodegenerative condition (amyotrophic lateral sclerosis, etc.). 3. Seizure disorder. 4. Other infectious, metabolic or systemic diseases affecting the central nervous system (syphilis, present hypothyroidism, present vitamin B12 or folate deficiency, other laboratory values etc.). * Any major psychiatric diagnosis, including schizophrenia, bipolar disorder, and current major depressive disorder as per Diagnostic and Statistical Manual of Mental Disorders Fifth Edition * Clinically significant, advanced or unstable disease that may interfere with outcome evaluations.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dementia with lewy bodies are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

dementia Lewy body dementia Lewy Body Disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dementia with lewy bodies

Contacts and locations

Locations

  • Banner Sun Health Research Institute

    Sun City, Arizona, 85351, United States

  • Barrow Neurological Institute

    Phoenix, Arizona, 85013, United States

  • CenExel Rocky Mountain Clinical Research, LLC

    Englewood, Colorado, 80113, United States

  • Charter Research

    Lady Lake, Florida, 32156, United States

  • Charter Research

    Winter Park, Florida, 32792, United States

  • Cleveland Clinic Main Campus

    Cleveland, Ohio, 44195, United States

  • Clinical Trial Network

    Houston, Texas, 77074, United States

  • Columbia University

    New York, New York, 10032, United States

  • Evergreen Health Research

    Kirkland, Washington, 98034, United States

  • Headlands Research Eastern Massachusetts, LLC

    Plymouth, Massachusetts, 02360, United States

  • IU Health Neuroscience Center, Goodman Hall

    Indianapolis, Indiana, 46202, United States

  • JEM Research Institute

    Atlantis, Florida, 33462, United States

  • Josephson Wallack Munshower Neurology, P.C

    Indianapolis, Indiana, 46256, United States

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

  • New England Institute for Neurology and Headache (NEINH)

    Stamford, Connecticut, 06905, United States

  • Ohio State University

    Columbus, Ohio, 43210, United States

  • Oregon Health and Science University

    Portland, Oregon, 97239, United States

  • Pacific Neuroscience Institute

    Santa Monica, California, 90404, United States

  • Parkinson's Disease and Movement Disorders Center of Boca Raton

    Boca Raton, Florida, 33486, United States

  • Renstar Medical Research

    Ocala, Florida, 34770, United States

  • Rush University Medical Center Section of Parkinson Disease and Movement Disorder

    Chicago, Illinois, 60612, United States

  • Stanford University

    Palo Alto, California, 94304, United States

  • Summit Headlands, LLC

    Portland, Oregon, 97210, United States

  • The University of Kansas Alzheimer's Disease Research Center

    Fairway, Kansas, 66205, United States

  • UNC Department of Neurology

    Chapel Hill, North Carolina, 27599, United States

  • University of Arizona - Health Sciences Center

    Tucson, Arizona, 85724, United States

  • University of Colorado

    Aurora, Colorado, 80045, United States

  • University of Kentucky

    Lexington, Kentucky, 40504, United States

  • University of Miami Miller School of Medicine Comprehensive Center for Brain Health

    Boca Raton, Florida, 33433, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19107, United States

  • University of Texas Southwestern

    Dallas, Texas, 75390, United States

  • University of Virginia Adult Neurology

    Charlottesville, Virginia, 22903, United States

  • Universtiy of Washington Department of Neurology

    Seattle, Washington, 98104, United States

  • Virginia Commonwealth University

    Richmond, Virginia, 23298, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.